Reviewing Oncology Pharma (OTCMKTS:ONPH) & CoreCard (NYSE:CCRD)

Oncology Pharma (OTCMKTS:ONPHGet Rating) and CoreCard (NYSE:CCRDGet Rating) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, earnings, valuation, risk, profitability, analyst recommendations and dividends.

Risk & Volatility

Oncology Pharma has a beta of -1.49, suggesting that its share price is 249% less volatile than the S&P 500. Comparatively, CoreCard has a beta of 0.86, suggesting that its share price is 14% less volatile than the S&P 500.

Insider & Institutional Ownership

49.6% of CoreCard shares are owned by institutional investors. 18.0% of Oncology Pharma shares are owned by insiders. Comparatively, 18.9% of CoreCard shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Profitability

This table compares Oncology Pharma and CoreCard’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Oncology Pharma N/A N/A N/A
CoreCard 25.54% 36.95% 27.54%

Valuation and Earnings

This table compares Oncology Pharma and CoreCard’s revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Oncology Pharma N/A N/A N/A N/A N/A
CoreCard $48.25 million 4.49 $9.04 million $1.92 13.08

CoreCard has higher revenue and earnings than Oncology Pharma.

Analyst Ratings

This is a summary of current recommendations and price targets for Oncology Pharma and CoreCard, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Oncology Pharma 0 0 0 0 N/A
CoreCard 0 0 1 0 3.00

CoreCard has a consensus target price of $50.00, suggesting a potential upside of 99.12%. Given CoreCard’s higher probable upside, analysts clearly believe CoreCard is more favorable than Oncology Pharma.

Summary

CoreCard beats Oncology Pharma on 9 of the 9 factors compared between the two stocks.

About Oncology Pharma

(Get Rating)

Oncology Pharma Inc., an oncology company, develops, manufactures, and commercializes therapeutics. The company has a collaboration and licensing agreement with Kalos Therapeutics Inc. for exploring treatment opportunities of the COVID-19 virus. The company was formerly known as SourcingLink.net Inc. and changed its name to Oncology Pharma Inc. in June 2019. Oncology Pharma Inc. was incorporated in 1993 and is based in San Francisco, California.

About CoreCard

(Get Rating)

CoreCard Corporation, together with its subsidiaries, offers technology solutions and processing services to the financial technology and services market in the United States, European Union, and the Middle East. It designs, develops, and markets a suite of software solutions to program managers, accounts receivable businesses, financial institutions, retailers, and processors to manage their credit and debit cards, prepaid cards, private label cards, fleet cards, buy now pay later programs, loyalty programs, and accounts receivable and loan transactions. The company's software solutions allow companies to offer various types of transacting account or card issuing program, as well as installment and revolving loans; set up and maintain account data; record advances and payments; assess fees, interests, and other charges; resolve disputes and chargebacks; manage collections of accounts receivable; generate reports; and settle transactions with financial institutions and network associations. The company was formerly known as Intelligent Systems Corporation and changed its name to CoreCard Corporation in December 2021. CoreCard Corporation was founded in 1973 and is headquartered in Norcross, Georgia.

Receive News & Ratings for Oncology Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oncology Pharma and related companies with MarketBeat.com's FREE daily email newsletter.